Takeichi Yoshida

Takeichi Yoshida

Auto-generated profile, based on publicly available information

Takeichi Yoshida

Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2020 in Gut and Liver
Verified
Journal Article
Open access
PDF file
YASUNOBU YAMASHITAYASUNOBU YAMASHITA
YASUNOBU YAMASHITA
KTKensuke Tanioka
Kensuke Tanioka
YKYuki Kawaji
Yuki Kawaji
Takashi TamuraTakashi Tamura
Takashi Tamura
JNJunya Nuta
Junya Nuta
MKMasayuki Kitano
Masayuki Kitano
Yasunobu Yamashita, Kensuke Tanioka, Yuki Kawaji, Takashi Tamura, Junya Nuta, Keiichi Hatamaru, Masahiro Itonaga, Takeichi Yoshida, Yoshiyuki Ida, Takao Maekita, Mikitaka Iguchi, and Masayuki Kitano. Gut and Liver 1999;0:. https://doi.org/10.5009/gnl19170

26 August 2026 in Cancer Discovery
Verified
Journal Article
Closed access
SHS. Daniel Haldar
S. Daniel Haldar
AHAmanda L. Huff
Amanda L. Huff
HWHejia Henry Wang
Hejia Henry Wang
ZZZirui Zhu
Zirui Zhu
MBMaureen Berg
Maureen Berg
NZNeeha Zaidi
Neeha Zaidi
Pancreatic ductal adenocarcinoma (PDAC) arises from precursor lesions over a decade-plus, offering a window for interception in high-risk individuals, but current surveillance detects a minority of precursors. Mutant KRAS (mKRAS) is present in most PDACs and their precursors, making it an appealing target for immune-based interception. We conducted a phase I, first-in-human study of a peptide vaccine targeting 6 common KRAS mutations (mKRAS-VAX) in 20 individuals with hereditary PDAC predisposition and a radiographic pancreatic abnormality (NCT05013216) to assess safety, immunogenicity, and T-cell persistence. Adverse events were grade 1 to 2. Vaccination elicited a significant mKRAS-specific T-cell response in 18 of 20 (90%) participants. Longitudinal T-cell receptor sequencing demonstrated persistence of vaccine-induced mKRAS-specific clonotypes for up to 2 years. Over a median follow-up of 16.5 months, no participants developed PDAC. These findings demonstrate that mKRAS-VAX is safe and generates durable T-cell responses, which support the advancement of mKRAS-targeted vaccination for PDAC interception. Significance: In high-risk individuals with hereditary predisposition to PDAC, a first-in-human peptide vaccine targeting mKRAS (mKRAS-VAX) was safe and elicited durable T-cell responses, supporting further development of mKRAS-targeted vaccination for immune interception for pancreatic precancers.

30 September 2025 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Closed access
YHYuto Hozaka
Yuto Hozaka
AMAnne Macgregor-Das
Anne Macgregor-Das
MHMasataka Hayashi
Masataka Hayashi
TYTakeichi Yoshida
Takeichi Yoshida
ABAmanda Blackford
Amanda Blackford
MGMichael Goggins
Michael Goggins
Background: Cancer antigen 125 (CA125) is widely recognized as a useful biomarker for the surveillance of patients with ovarian and other cancers. Prior genome-wide association studies have identified variants that influence CA125 levels. We evaluated the utility of stratifying CA125 levels by such variants and evaluated diagnostic performance in control subjects and patients with pancreatic ductal adenocarcinoma (PDAC). Methods: We measured CA125 levels in 807 control subjects and 450 patients with PDAC and genotyped 10 variants involving four genes (GAL3ST2, MSLN, D2HGDH, and MUC16). We compared CA125 levels in controls by variant and generated variant-defined CA125 cutoffs and then classified cases and controls into functional groups based on their variant profile. We used this variant classification to evaluate the diagnostic performance of CA125 in patients with PDAC. Results: Six variants associated with CA125 levels were used to group controls into one of four groups. Mean CA125 levels in the highest variant group were approximately fourfold higher than in the lowest group. African Americans were more likely to have a variant group associated with low CA125 levels. After setting diagnostic cutoffs by variant group, the diagnostic sensitivity of CA125 for PDAC was 20.2% at 98% specificity (areas under the ROC curve, 0.702), not significantly different from a uniform CA125 diagnostic cutoff (areas under the ROC curve, 0.700). Conclusions: Gene variants can be used to generate personalized CA125 reference ranges. This approach did not significantly improve CA125’s diagnostic performance for pancreatic cancer, but it merits evaluation in other diagnostic settings, such as detecting ovarian cancer. Impact: Gene variants can be used to personalize CA125 levels.

1 December 2025
Verified
Other
Open access
YHYuto Hozaka
Yuto Hozaka
AMAnne Macgregor-Das
Anne Macgregor-Das
MHMasataka Hayashi
Masataka Hayashi
TYTakeichi Yoshida
Takeichi Yoshida
ABAmanda Blackford
Amanda Blackford
MGMichael Goggins
Michael Goggins
Supplementary Table S2: Clinicopathological features and CA125 levels in controls and patients with PDAC

1 December 2025
Verified
Other
Open access
YHYuto Hozaka
Yuto Hozaka
AMAnne Macgregor-Das
Anne Macgregor-Das
MHMasataka Hayashi
Masataka Hayashi
TYTakeichi Yoshida
Takeichi Yoshida
ABAmanda Blackford
Amanda Blackford
MGMichael Goggins
Michael Goggins
Supplementary Figure S4: CA125 levels by variant group

1 December 2025
Verified
Other
Open access
PDF file
YHYuto Hozaka
Yuto Hozaka
AMAnne Macgregor-Das
Anne Macgregor-Das
MHMasataka Hayashi
Masataka Hayashi
TYTakeichi Yoshida
Takeichi Yoshida
ABAmanda Blackford
Amanda Blackford
MGMichael Goggins
Michael Goggins
Supplementary Table S6: Clinical features of PDAC cases with true positive vs false negative CA125 levels (variant-based classification)